{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.7"},{"groupId":"OG001","value":"0.0"}]}],"title":"Grade 0"},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.5"},{"groupId":"OG001","value":"2.7"}]}],"title":"Grade 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.9"},{"groupId":"OG001","value":"6.8"}]}],"title":"Grade 2"},{"categories":[{"measurements":[{"groupId":"OG000","value":"24.0"},{"groupId":"OG001","value":"15.1"}]}],"title":"Grade 3"},{"categories":[{"measurements":[{"groupId":"OG000","value":"56.8"},{"groupId":"OG001","value":"75.3"}]}],"title":"Missing Grade"}],"denoms":[{"counts":[{"groupId":"OG000","value":"146"},{"groupId":"OG001","value":"73"}],"units":"Participants"}],"description":"This was noted as fibrosis density and was tabulated by fibrosis grade at baseline and at week 48 (post-baseline). Descriptive statistics (participant percentages) were used.\n\nFibrosis grades: 0 Scattered linear reticulin with no intersections corresponding to normal bone marrow ; 1 Loose network of reticulin with many intersections, especially in perivascular areas; 2 Diffuse and dense increase in reticulin with extensive intersections, occasionally with only focal bundles of collagen and/or focal osteosclerosis; 3 Diffuse and dense increase in reticulin with extensive intersections with coarse bundles of collagen, often associated with significant osteosclerosis","groups":[{"description":"5 milligram tablets administered orally in an outpatient setting according to the protocol-specified dosing schedule","id":"OG000","title":"Ruxolitinib"},{"description":"Commercially available therapy, oral or parenteral, per manufacturer's instructions and Investigator discretion. BAT included the option of no treatment.","id":"OG001","title":"Best Available Therapy (BAT)"}],"paramType":"NUMBER","populationDescription":"Full analysis set (FAS) consisted of all subjects who were randomized and put in strata according to International Working Group for Myelofibrosis Research and Treatment(IWG MRT) prognostic criteria.","reportingStatus":"POSTED","timeFrame":"48 weeks","title":"Percentage of Participants With Bone Marrow Histomorphology at Week 48 (Primary Analysis)","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}